#type1diabetes is an autoimmune disease in which a person’s own immune system attacks the insulin producing cells. One cannot live without this vital hormone and patients have to administer insulin using pens and pumps. Diamyd Medical try to make a difference for those newly diagnosed with Type 1 Diabetes. Check the recruiting #precisionmedicine phase III clinical trial DIAGNODE-3 at diagnode-3.com 💙 #T1D #Diabetes
Diamyd Medical’s Post
More Relevant Posts
-
Today at the 8th annual Heart in Diabetes we’re sharing more information about our GRACE clinical trial data in our presentation: Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study. Metabolic Endocrine Education Foundation #CortisolModulation #8thHeartinDiabetes #HID2024
To view or add a comment, sign in
-
-
Investigators have implemented an automated health maintenance tool, created by the National Kidney Foundation, into electronic medical records, to hasten the screening of chronic kidney disease in adult patients with type 2 diabetes by primary care physicians. This innovative clinical decision support tool automatically offers a one-click option for ordering crucial kidney disease screening tests, such as the urine-albumin-to-creatinine ratio (UACR) or plasmatic creatinine. The impact of this resource was evident in the University of Virginia Health System, demonstrating significantly higher rates of UACR testing during primary care encounters and surpassing groups not using similar automated tools. This achievement may represent a significant leap forward in proactive kidney disease diagnosis. Read more, here: https://lnkd.in/e4DhZMpm #Diaverum #ExpertCare #Truecare #CKD #Dialysis #MedicalResearch
To view or add a comment, sign in
-
-
BPH Patients Experience: Incomplete Emptying Urinary Frequency Intermittency Urinary Urgency Weak Stream Straining Nocturia Rezūm™ Water Vapor Therapy is Safe, Effective, Durable 5 Year Clinical Data to back it up: https://lnkd.in/e7NjaVSi
To view or add a comment, sign in
-
Bronchiectasis/NTM patient advocate, educator, author and influencer working with companies & educational institutions to recruit participants for clinical trials, surveys, interviews and focus groups
A flare up or an exacerbation is described as a deterioration of three or more of the following symptoms within a 48 hour period: 🌟cough 🌟 sputum, volume and/or consistency 🌟sputum purulence 🌟 breathlessness, and/or exercise tolerance 🌟 fatigue, and/or malaise 🌟 haemoptysis AND a determination by a clinician that a change in treatment is necessary. This includes the need for medication and/or increased airway clearance. The above definition of an exacerbation was included at the November 8th patient education program at NYU Langone. This definition comes from a panel of American, European and Australian bronchiectasis experts who convened in 2017 to address how a bronchiectasis exacerbation is defined for research purposes. Although this is currently a working definition, it’s always best to speak to your doctor about how he or she defines an exacerbation and what you should do if you feel you are having one. Remember, early intervention is key to managing bronchiectasis flare ups and maintaining overall health. For more information on flare ups, take a look at Insmed’s new website https://lnkd.in/eGhw7Kqy. On the website, you will see a symptom checklist tool. Insmed’s new drug brensocatib is part of a phase 3 trial (Aspen). They will be reporting their findings during the second quarter of 2024. If this drug comes to market, it will be a game-changer for many of us living with bronchiectasis!! Let’s follow Insmed on social media and stay updated (social media links on their website). #Insmed #Brensocatib #Bronchiectasis #Cough #Mucus #Phlegm #Sputum #ChronicLungDisease #ChronicLungIllness #ChronicCough #ClinicalTrials Insmed Incorporated
To view or add a comment, sign in
-
-
Encouraging preliminary data from Phase II trial in ALS suggesting a benefit to explore in further clinical trials. https://lnkd.in/ekvrhcsA
Raya Therapeutic
rayatherapeutic.com
To view or add a comment, sign in
-
Ever wondered why clinical trials are crucial for rare conditions like Congenital Myasthenic Syndromes (CMS)? 💭 "Clinical trials are the backbone of medical advancement. It's through these trials that we uncover the most effective treatments for conditions like CMS." For you, this means hope. Hope for new treatments, better quality of life, and hopefully one day, a cure. 💙 Clinical trials are not just for CMS but are key to unveiling solutions for many rare diseases. Remember, every step in research is a step closer to answers. 🔗 Read 'What You Need to Know about CMS and Clinical Trials' on The Know Rare Blog: https://lnkd.in/g4gE2Nv5 #CongenitalMyasthenicSyndromes #raredisease #rarediseases #medicalresearch #clinicaltrials #clinicaltrial #clinicalstudy #rarediseaseawareness #KnowRare
To view or add a comment, sign in
-
-
#HeartFailure2024 The consistency of the treatment benefit of remote hemodynamic monitoring in chronic heart failure: a predefined subgroup analysis of the randomised clinical Trial MONITOR-HF
To view or add a comment, sign in
-
-
Whole-Body Electrostatic Pain Treatment in Adults with Chronic Pain: A Prospective Multicentric Observational Clinical Trial https://lnkd.in/djKxJu8J
To view or add a comment, sign in
-
-
Improving testing and treatment for hepatitis can’t wait, and you can be a part of this process. This World Hepatitis Day, visit our resource library to find clinical trials and get the information you need to take part in clinical research. https://ow.ly/522u50Snxex #worldhepatitusday #clinicaltrials #clinicalresearch
To view or add a comment, sign in
-
Rare Disease Day is a global initiative to raise awareness and generate support for everyone who is on a rare medical journey. It takes place on the last day of February, which this year is February 29th, the rarest day of the year. Currently appropriate therapy is available for 5 percent of patients with rare diseases, and the lack of effective treatments presents additional difficulties for those affected and their treating physicians. This highlights the need for medical and clinical research in this area, but there are serious challenges to overcome - starting with the lack of profitability, limited knowledge of the disease, to difficulty of patient enrolment to clinical trials. #rarediseaseday #clinicaltrials
To view or add a comment, sign in
-